Determining the optimal dry powder adenosine provocation test to assess small airways disease

Determining the optimal dry powder adenosine provocation test to assess small airways disease - Impact

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON38368

Enrollment

Registered

2012-06-18

Start date

2012-06-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma inflammation of the airways

Interventions

Participating subjects perform 4 provocation tests in randomized order: one time inhaling nebulized AMP, and four times dry powder adenosine. one test contains small particles (MMAD 2,5-3mcm) and a

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • A docter*s diagnosis of asthma • Age: 18-65 years • PC20 methacholine-bromide

Exclusion criteria

Exclusion criteria: • Steroid use 4 weeks before entry into the baseline period • Recent exacerbation asthma (

Design outcomes

Primary

Measure	Time frame
The major endpoint of the study is the change in small airways resistance during the provocation tests, clarified as R5-R20 measured with IOS (impulse oscillometry). Other endpoints of this study are the decline in FVC at 20% fall in FEV1, and the PD20/PC20 values.	—

Secondary

Measure	Time frame
Other endpoints of this study are the decline in FVC at 20% fall in FEV1, and the PD20/PC20 values.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)